BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30175971)

  • 1. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
    Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
    Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
    Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M
    Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
    Peng W; Wu J; Feng J
    Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
    Peng W; Wu J; Feng J
    Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis.
    Yuan J; Yang J; Wang R; Hao H; Li J
    Immunopharmacol Immunotoxicol; 2022 Jun; 44(3):429-436. PubMed ID: 35352617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
    [No Abstract]   [Full Text] [Related]  

  • 9. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity.
    Peng W; Fan H; Wu G; Wu J; Feng J
    Clin Exp Med; 2016 May; 16(2):177-82. PubMed ID: 25864113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma.
    Peng W; Feng J
    Biomed Pharmacother; 2016 Feb; 77():65-71. PubMed ID: 26796267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
    Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
    Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.
    Chen W; Wang H; Chen H; Liu S; Lu H; Kong D; Huang X; Kong Q; Lu Z
    Eur J Haematol; 2014; 92(5):407-12. PubMed ID: 24400911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression.
    Yang W; Li Y; Li P; Wang L
    Oncol Rep; 2016 Aug; 36(2):1069-75. PubMed ID: 27349720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA NEAT1 overexpression is associated with unfavorable prognosis in patients with hepatocellular carcinoma after hepatectomy: A Chinese population-based study.
    Liu Z; Chang Q; Yang F; Liu B; Yao HW; Bai ZG; Pu CS; Ma XM; Yang Y; Wang TT; Guo W; Zhou XN; Zhang ZT
    Eur J Surg Oncol; 2017 Sep; 43(9):1697-1703. PubMed ID: 28732670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
    Lv X; Feng L; Ge X; Lu K; Wang X
    J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma.
    Ning L; Li Z; Wei D; Chen H; Yang C
    Cancer Biomark; 2017; 19(1):75-83. PubMed ID: 28269753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of miR-126 in Diffuse Large B-Cell Lymphoma and Its Biological Function].
    Qiu C; Zhang QH; Wang GG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1415-1422. PubMed ID: 36208243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma.
    Wang WL; Yang C; Han XL; Wang R; Huang Y; Zi YM; Li JD
    Med Oncol; 2014 Apr; 31(4):919. PubMed ID: 24659264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.